SCHEMBL25281989

SCHEMBL25281989

Cc1nc(C(=O)O)nn1-c1nc(N2CCNCC2)ncc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 12/20 0.40
▸ HSD17B10 Q99714 11/20 0.40
▸ HPGD P15428 7/20 0.40
▸ TSHR P16473 6/20 0.40
▸ MAPT P10636 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MAPK1 P28482 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CYP1A2 P05177 10/20 0.38
▸ CASP1 P29466 8/20 0.38
▸ CASP7 P55210 8/20 0.38
▸ CYP3A4 P08684 6/20 0.38
▸ CYP2C19 P33261 5/20 0.38
▸ USP2 O75604 5/20 0.37
▸ CYP2C9 P11712 6/20 0.36
▸ HIF1A Q16665 3/20 0.36
▸ BCL6 P41182 1/20 0.36
▸ GLA P06280 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24054410 0.87 GBA1 (0.37) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL25284926 0.83 KDM4E (0.45) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL30166472 0.83 KDM4E (0.45) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL25278577 0.81 KDM4E (0.40) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL30166327 0.81 GPR119 (0.48) MAPTLMNA
SCHEMBL25238108 0.81 GPR119 (0.48) MAPTLMNA
SCHEMBL24054344 0.80 KDM4E (0.44) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL24053877 0.79 KDM4E (0.40) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL25695425 0.79 SMN1; SMN2 (0.43) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL25695335 0.78 ALDH1A1 (0.41) ALDH1A1HSD17B10HPGDTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454529-B2 Piperazine cyclic ureas Sironax Ltd. (KY) 2025-10-28 — — US disclosed
CN-115697991-B Piperazine cyclic ureas 维泰瑞隆有限公司 2024-11-22 — — CN disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 — — US disclosed
CN-115697991-A Piperazine cyclic ureas 维泰瑞隆有限公司 2023-02-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454529-B2 Piperazine cyclic ureas RIPK1, RIPK3, RIPK4 ALDH1A1 3602/4885HSD17B10 4253/4885HPGD 1224/4885
US-20230203019-A1 Piperazine Cyclic Ureas RIPK1, RIPK3, RIPK4 ALDH1A1 3602/4885HSD17B10 4253/4885HPGD 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback